Combinostics today announced the release of cNeuro® cMRI 2.0 and cNeuro® cDSI 2.0. The main benefit of the new release is modularization of the system, facilitating the introduction of additional products to the cNeuro suite.
Combinostics new PET quantification application cNeuro cPET receives FDA 510(k) clearance
New cPET application for amyloid and FDG brain PET quantification further extends Combinostics’ solutions across the entire patient pathway for neurological disorders and supports end-to-to-end workflows.
